Ernexa Therapeutics saw its shares rise 30% on Wednesday following publication of independent preclinical validation data for its lead cell therapy candidate, ERNA-101, in ovarian cancer models.
An independent contract research organization reported reproduction of prior results, documenting complete tumor clearance and durable survival in a larger preclinical experiment. When ERNA-101 was paired with anti-PD-1 therapy, 10 of 15 treated animals - or 67% - achieved complete tumor clearance and long-term survival. By contrast, none of the remaining 45 animals in the study experienced complete tumor clearance or durable survival when treated with ERNA-101 alone, anti-PD-1 alone, or left untreated.
The independent work mirrored earlier findings produced at The University of Texas Anderson Cancer Center and provides third-party validation as the company advances regulatory and clinical plans. Ernexa is targeting an Investigational New Drug submission in the third quarter of 2026 and anticipates initiating a first-in-human Phase 1 clinical trial in the fourth quarter of 2026.
The study employed an immunocompetent ID8luc-ova syngeneic ovarian cancer model. Investigators tracked tumor burden using bioluminescence imaging to monitor treatment responses and to confirm instances of complete tumor clearance.
Prior preclinical research had shown that ERNA-101 homes selectively to ovarian tumors and delivers an engineered IL-7/IL-15 fusion cytokine into the tumor microenvironment. That localized cytokine delivery was associated with heightened infiltration of T cells that can target cancer cells, improving immune recognition in tumors that typically evade immune detection.
Ernexa develops cell therapies intended to treat advanced cancers and autoimmune conditions. The newly reported independent replication of ERNA-101 results reinforces the preclinical profile the company has presented to date and supports its stated regulatory timeline.
Methodological notes
- The replication study was conducted by an independent contract research organization using the same immunocompetent syngeneic model cited in prior research.
- Tumor response assessment relied on bioluminescence imaging to quantify tumor burden and identify complete clearance events.
- Outcome measures contrasted combination therapy against monotherapies and no treatment across 60 animals in total.
Market context
The stock reaction followed publication of the independent dataset showing reproducible complete tumor clearance and durable survival in the combination treatment arm. The validated preclinical results are cited by the company as supportive evidence as it prepares for regulatory submission and subsequent clinical testing.